Brokerages Set Calumet, Inc. (NASDAQ:CLMT) Target Price at $48.00

Calumet, Inc. (NASDAQ:CLMT) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $51.75.

A number of analysts have recently weighed in on CLMT shares. TD Cowen raised their price target on shares of Calumet from $34.00 to $40.00 and gave the company a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Calumet in a research note on Friday, August 7th. The Goldman Sachs Group increased their target price on shares of Calumet from $40.00 to $45.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. HC Wainwright lifted their price target on shares of Calumet from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Finally, UBS Group lifted their price target on shares of Calumet from $26.00 to $47.00 and gave the stock a “neutral” rating in a report on Tuesday, August 25th.

Trending Headlines about Calumet

Here are the key news stories impacting Calumet this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its Q3 2026 EPS estimate to $0.62 from $0.60, Q4 to $0.24 from $0.22, FY2026 to $0.17 from $0.12, and FY2027 to $1.11 from $0.59. Its $75 price target implies substantial upside from the stock’s recent trading level. HC Wainwright earnings estimate report
• Positive Sentiment: The upward revisions suggest HC Wainwright expects stronger profitability over the next several quarters, potentially reflecting improved operating performance or business conditions. The revised FY2027 forecast is notably above the broader current-year consensus estimate of $0.46 per share. Calumet stock price expected to rise
• Neutral Sentiment: Calumet announced plans to attend the H.C. Wainwright conference. The event could provide investors with updates on strategy and operations, but no new financial information was disclosed in the announcement. Calumet conference announcement
• Neutral Sentiment: A Zacks analysis compared Calumet’s year-to-date performance with TXO Partners and the broader oil-and-energy sector. The article provides relative-performance context but does not indicate a new company-specific catalyst. Zacks Calumet sector performance analysis
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Calumet investors. Although the announcement does not establish wrongdoing, the prospect of litigation or regulatory concerns may weigh on sentiment and introduce uncertainty. Pomerantz investor investigation

Insiders Place Their Bets

In related news, Director Daniel Sajkowski sold 4,240 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $36.16, for a total transaction of $153,318.40. Following the transaction, the director directly owned 77,718 shares of the company’s stock, valued at $2,810,282.88. This represents a 5.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 3.15% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Calumet

Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its position in shares of Calumet by 36.6% in the 2nd quarter. Legal & General Group Plc now owns 72,143 shares of the oil and gas company’s stock valued at $1,137,000 after purchasing an additional 19,322 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Calumet during the 2nd quarter worth approximately $343,000. Quantbot Technologies LP acquired a new position in Calumet during the 2nd quarter valued at approximately $241,000. Invesco Ltd. increased its stake in Calumet by 514.8% during the 2nd quarter. Invesco Ltd. now owns 94,642 shares of the oil and gas company’s stock valued at $1,491,000 after purchasing an additional 79,247 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Calumet by 199.9% during the second quarter. The Manufacturers Life Insurance Company now owns 34,551 shares of the oil and gas company’s stock valued at $544,000 after buying an additional 23,031 shares during the last quarter. Institutional investors and hedge funds own 34.41% of the company’s stock.

Calumet Price Performance

NASDAQ:CLMT opened at $53.13 on Wednesday. The firm has a market cap of $4.67 billion, a PE ratio of -34.28 and a beta of 0.72. The company has a 50-day moving average of $43.76 and a 200 day moving average of $36.26. Calumet has a 1-year low of $16.75 and a 1-year high of $54.69.

Calumet (NASDAQ:CLMT) last announced its quarterly earnings results on Friday, August 7th. The oil and gas company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($1.16). The firm had revenue of $1.45 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the firm earned ($1.70) earnings per share. The business’s revenue for the quarter was up 40.8% on a year-over-year basis. Sell-side analysts anticipate that Calumet will post 0.48 EPS for the current fiscal year.

Calumet Company Profile

Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.

Calumet’s product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.